stoxline Quote Chart Rank Option Currency Glossary
  
Adicet Bio, Inc. (ACET)
0.67  0.001 (0.15%)    06-20 16:00
Open: 0.675
High: 0.677
Volume: 269,459
  
Pre. Close: 0.669
Low: 0.66
Market Cap: 55(M)
Technical analysis
2025-06-20 4:38:10 PM
Short term     
Mid term     
Targets 6-month :  0.88 1-year :  0.98
Resists First :  0.75 Second :  0.83
Pivot price 0.74
Supports First :  0.62 Second :  0.52
MAs MA(5) :  0.69 MA(20) :  0.73
MA(100) :  0.75 MA(250) :  1.05
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  11.2 D(3) :  23.9
RSI RSI(14): 44.2
52-week High :  1.7 Low :  0.44
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ACET ] has closed above bottom band by 8.6%. Bollinger Bands are 20.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.68 - 0.68 0.68 - 0.69
Low: 0.65 - 0.65 0.65 - 0.66
Close: 0.66 - 0.67 0.67 - 0.68
Company Description

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

Headline News

Mon, 26 May 2025
Adicet Bio’s SWOT analysis: gamma-delta T cell therapy stock faces pivotal year - Investing.com

Fri, 09 May 2025
Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know - Nasdaq

Wed, 07 May 2025
Adicet Bio Reports Q1 2025 Results and Updates - TipRanks

Tue, 06 May 2025
Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates - Business Wire

Mon, 28 Apr 2025
Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting - BioSpace

Sun, 27 Apr 2025
We're Keeping An Eye On Adicet Bio's (NASDAQ:ACET) Cash Burn Rate - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 83 (M)
Shares Float 61 (M)
Held by Insiders 2.7 (%)
Held by Institutions 67.6 (%)
Shares Short 2,370 (K)
Shares Short P.Month 2,060 (K)
Stock Financials
EPS -1.29
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.95
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -32.7 %
Return on Equity (ttm) -55.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.46
Qtrly Earnings Growth 0 %
Operating Cash Flow -95 (M)
Levered Free Cash Flow -56 (M)
Stock Valuations
PE Ratio -0.52
PEG Ratio 0
Price to Book value 0.34
Price to Sales 0
Price to Cash Flow -0.59
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android